These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 10777696

  • 1. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK.
    Mukohyama H, Ransjö M, Taniguchi H, Ohyama T, Lerner UH.
    Biochem Biophys Res Commun; 2000 Apr 29; 271(1):158-63. PubMed ID: 10777696
    [Abstract] [Full Text] [Related]

  • 2. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
    Kaji H, Kanatani M, Sugimoto T, Chihara K.
    Horm Metab Res; 2005 Oct 29; 37(10):589-92. PubMed ID: 16278780
    [Abstract] [Full Text] [Related]

  • 3. Regulation of osteoclastogenesis by gap junction communication.
    Matemba SF, Lie A, Ransjö M.
    J Cell Biochem; 2006 Oct 01; 99(2):528-37. PubMed ID: 16639710
    [Abstract] [Full Text] [Related]

  • 4. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
    Kanatani M, Sugimoto T, Sowa H, Kobayashi T, Kanzawa M, Chihara K.
    J Cell Physiol; 2004 Oct 01; 201(1):17-25. PubMed ID: 15281085
    [Abstract] [Full Text] [Related]

  • 5. The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts.
    Persson E, Lerner UH.
    J Cell Biochem; 2011 Dec 01; 112(12):3732-41. PubMed ID: 21815197
    [Abstract] [Full Text] [Related]

  • 6. Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol.
    Ishizuka K, Hirukawa K, Nakamura H, Togari A.
    Neurosci Lett; 2005 Apr 29; 379(1):47-51. PubMed ID: 15814197
    [Abstract] [Full Text] [Related]

  • 7. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
    Lossdörfer S, Schwartz Z, Wang L, Lohmann CH, Turner JD, Wieland M, Cochran DL, Boyan BD.
    J Biomed Mater Res A; 2004 Sep 01; 70(3):361-9. PubMed ID: 15293309
    [Abstract] [Full Text] [Related]

  • 8. Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor.
    Yamada N, Tsujimura T, Ueda H, Hayashi S, Ohyama H, Okamura H, Terada N.
    Cytokine; 2005 Aug 21; 31(4):288-97. PubMed ID: 15996478
    [Abstract] [Full Text] [Related]

  • 9. [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts].
    Tian QX, Huang GY.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug 21; 26(4):418-22. PubMed ID: 15379268
    [Abstract] [Full Text] [Related]

  • 10. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
    Wada N, Maeda H, Yoshimine Y, Akamine A.
    Bone; 2004 Sep 21; 35(3):629-35. PubMed ID: 15336598
    [Abstract] [Full Text] [Related]

  • 11. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM, Pearse RN.
    Cancer; 2003 Feb 01; 97(3 Suppl):802-12. PubMed ID: 12548579
    [Abstract] [Full Text] [Related]

  • 12. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
    Kanatani M, Sugimoto T, Kano J, Kanzawa M, Chihara K.
    J Cell Physiol; 2003 Jul 01; 196(1):180-9. PubMed ID: 12767054
    [Abstract] [Full Text] [Related]

  • 13. [New paradigms in the regulation of bone metabolism].
    Rosa-Rañal M, de la Cruz DA, Lorena-Rubio Y, Larrea F.
    Rev Invest Clin; 2001 Jul 01; 53(4):362-9. PubMed ID: 11599485
    [Abstract] [Full Text] [Related]

  • 14. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
    Swanson C, Lorentzon M, Conaway HH, Lerner UH.
    Endocrinology; 2006 Jul 01; 147(7):3613-22. PubMed ID: 16614077
    [Abstract] [Full Text] [Related]

  • 15. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
    Xiao XH, Zhou HD, Yuan LQ, Xie H, Liao EY.
    Zhonghua Yi Xue Za Zhi; 2004 Dec 17; 84(24):2102-6. PubMed ID: 15730627
    [Abstract] [Full Text] [Related]

  • 16. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
    Atkins GJ, Kostakis P, Welldon KJ, Vincent C, Findlay DM, Zannettino AC.
    J Cell Physiol; 2005 Jun 17; 203(3):573-82. PubMed ID: 15573398
    [Abstract] [Full Text] [Related]

  • 17. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines.
    Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H.
    Biochem Biophys Res Commun; 2000 Sep 07; 275(3):768-75. PubMed ID: 10973797
    [Abstract] [Full Text] [Related]

  • 18. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin.
    Shiotani A, Takami M, Itoh K, Shibasaki Y, Sasaki T.
    Anat Rec; 2002 Oct 01; 268(2):137-46. PubMed ID: 12221720
    [Abstract] [Full Text] [Related]

  • 19. Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation.
    Smith R, Ransjö M, Tatarczuch L, Song SJ, Pagel C, Morrison JR, Pike RN, Mackie EJ.
    J Bone Miner Res; 2004 Mar 01; 19(3):507-16. PubMed ID: 15040840
    [Abstract] [Full Text] [Related]

  • 20. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
    Koh JM, Lee YS, Byun CH, Chang EJ, Kim H, Kim YH, Kim HH, Kim GS.
    J Endocrinol; 2005 Jun 01; 185(3):401-13. PubMed ID: 15930166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.